Importantly, a significant portion of the cases we identified were related to lifelong cancer risk (e.g., TP53, NF2, NRAS, PTEN, and MSH6), affecting both informed anticipatory follow-up and anticancer treatment regimens for these children and their families (Zhang et al., 2015; Scollon et al., 2021). This evidence concerns the gene NRAS and cancer.